[Sézary syndrome (author's transl)].
Morphological demonstration of the typical Sézary cell in peripheral blood confirmed the diagnosis of Sézary syndrome in a 64-year-old patient with generalized erythrodermia and typical histopathological skin changes. Enzymes and immunocytological membrane characteristics of Sézary cells changed in the course of the disease after cytostatic therapy. Polychemotherapy clinically led to transitory complete regression of skin changes. Reviewing the few published investigations it is found that the morphologically sufficiently defined Sézary cells are apparently not uniform cytochemically and immunocytologically in different patients.
D001344:Autopsy; D001706:Biopsy; D003520:Cyclophosphamide / Q000627:therapeutic use; D005448:Fluocortolone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D012751:Sezary Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D012867:Skin / Q000473:pathology; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D005448:Fluocortolone; D003520:Cyclophosphamide
Sézary-Syndrom. Variabilität der immunzytologischen und zytochemischen diagnostischen Parameter.